Bio Rad Laboratories Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Bio Rad Laboratories Inc in the second quarter 2026?
Bio rad Laboratories Inc achieved a return on average equity (ROE) of 3.15 % in its second quarter 2026, which is below Bio Rad Laboratories Inc 's average return on equity, which stands at 6.7%.

ROE has advanced compared to 2.4% in the first quarter 2026, due to net income growth.

Within the Laboratory Analytical Instruments industry 5 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1246 to 2142.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	0.63 %	2.57 %	13.46 %	-10.03 %	-
Y / Y Net Income Change	16.87 %	-	-	-	-
Net Income (TTM) in Millions	222	169	760	-676	319
Return On Equity (TTM)	3.15 %	2.4 %	10.86 %	-9.97 %	4.58 %
BIO's Total Ranking	# 2142	# 1246	# 1161	# 517	# 1677
Equity (TTM) in Millions	7,174	6,851	7,454	6,737	7,129
Seq. Equity Change	4.71 %	-8.08 %	10.64 %	-5.5 %	6.73 %
Seq. Net Income Change	-	-	-	-	396.56 %

Back to BIO Management Effectiveness >> BIO's 5 Years Annual ROE >> Compare BIO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 6
Sector	# 174
Overall	# 2142

Return On Equity Statistics
High	Average	Low
56.17 %	6.7 %	-58.55 %
(Sep 30 2021)		(Sep 30 2022)

BIO Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	7,454	6,569	8,741	9,615	13,667
Y / Y Equity Change	13.46 %	-24.85 %	-9.09 %	-29.65 %	38.33 %
Net Income in Millions	760	-1,844	-637	-3,628	4,246
Y / Y Net Income Change	-	-	-	-	11.55 %
Return On Equity	10.2 %	-28.07 %	-7.29 %	-37.73 %	31.07 %

Back to BIO Management Effectiveness >> BIO's 5 Years Annual ROE >> Compare BIO ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 10.2 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BIO's' Return on Equity at Yahoo Finance
BIO's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BIO's Competitors
Subscribers only: Roe for Bio Rad Laboratories Inc 's Suppliers
Subscribers only: Return On Equity for BIO's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Vaso Corporation	8.65 %
Veracyte Inc	8.64 %
Corcept Therapeutics Inc	8.27 %
Integer Holdings Corporation	7.43 %
Pacific Health Care Organization Inc	7.42 %
Vericel Corporation	6.91 %
The Cooper Companies Inc	6.90 %
Siga Technologies Inc	6.74 %
Merck and Co Inc	6.59 %
Zimmer Biomet Holdings Inc	6.36 %
National Vision Holdings Inc	5.71 %
Conmed Corporation	5.51 %
Pfizer Inc	4.91 %
Privia Health Group Inc	4.23 %
Becton Dickinson And Company	3.79 %
Alkermes Plc	3.72 %
Lifemd Inc	3.47 %
Lifestance Health Group Inc	3.39 %
Revvity Inc	3.27 %
Bio rad Laboratories Inc	3.15 %
Envista Holdings Corporation	3.08 %
Immucell Corporation	2.68 %
Surgery Partners Inc	2.63 %
Mimedx Group Inc	2.61 %
Cormedix Inc	2.18 %
Atricure Inc	2.14 %
Pacira Biosciences inc	2.13 %
Warby Parker Inc	2.06 %
Repligen Corp	1.98 %
Arvinas Inc	1.91 %

Date modified: 2026-09-12T06:19:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.